Article
MET FISH-positive status predicts short progression-free survival and overall survival after gefitinib treatment in lung adenocarcinoma with EGFR mutation.
BMC cancer - 6 Feb 2015
Noro Rintaro, Seike Masahiro, Zou Fenfei, Soeno Chie, Matsuda Kuniko, Sugano Teppei, Nishijima Nobuhiko, Matsumoto Masaru, Kitamura Kazuhiro, Kosaihira Seiji, Minegishi Yuji, Yoshimura Akinobu, Kubota Kaoru, Gemma Akihiko
Abstract excerpt
BACKGROUND: Lung adenocarcinoma patients with EGFR gene mutations have shown a dramatic response to gefitinib. However, drug resistance eventually emerges which limits the mean duration of response. With that in view, we examined the correlations between MET gene status as assessed by fluorescence in situ hybridization (FISH) with overall survival (OS) and progression-free survival (PFS) in adenocarcinoma...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
